Five Prime Therapeutics Completes Phase 1 Safety Lead-In and Initiates Phase 3 Global Registrational Trial of Bemarituzumab
SAGA Metals Announces Closing of Fully Subscribed Non-Brokered Private Placement and Provides Corporate Update